Herpes Zoster Treatment Market Statistics 2030:
The global herpes zoster treatment market size was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030. Herpes zoster, or shingles, is a common viral infection of the nerves caused by the varicella-zoster virus, which results in a painful rash of small blisters on a strip of skin anywhere on the body. Even after the rash is gone, the pain may continue for months. Shingles is more common in people with a depressed immune system and those over the age of 50. It's quite rare in children, and the symptoms are mild compared to what an adult may experience. After the person has had chicken pox, the virus lies dormant in certain nerves for years and its reactivation causes herpes zoster infection. herpes zoster is a sporadic disease with an estimated lifetime incidence of 10% to 20%. In addition, the incidence of herpes zoster increases sharply with advancing age, roughly doubling in each decade past the age of 50 years. Herpes zoster is uncommon in persons less than 15 years old.
Increase in the geriatric population coupled with rising incidence of herpes zoster is other factors that contribute toward the growth of the market. However, dearth of skilled professionals is expected to hinder the growth of the market. Conversely, increasing drug development provides lucrative growth opportunities to the market.
The global herpes zoster treatment market is segmented into treatment type, route of administration, distribution channel, and region. By treatment type, the market is categorized into antiviral medications, anti inflammatory medications, and others. On the basis of route of administration, it is segregated into oral and topical. Depending on distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Impact Of Covid-19 On Herpes Zoster Treatment Market (Pre And Post Analysis)
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which ranges from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. The COVID-19 pandemic is an unprecedented global public health challenge, and is anticipated to have a negative impact on herpes zoster treatment market to the lockdowns that were imposed in the first half of 2020, which resulted in disruption of the supply chain. In addition, fall in number of surgeries and reduced patient visits to hospitals, owing to change in healthcare priorities and as a prevention measure to avoid contracting the disease also resulted in drop in number of patients visiting hospitals for diseases other than COVID-19.
Overall, the impact of the COVID-19 pandemic on the herpes zoster treatment market was reported to be negative. This was attributed to factors such as difficulty in management of diagnosis and treatment of herpes zoster, which require hospital stay, prolong recovery time in COVID-19 conditions and delay in treatment. However, this impact is expected to change post COVID-19 pandemic, and is expected to increase growth of the market.
Treatment Type Segment Review
Based on treatment type, the herpes zoster treatment market is categorized into antiviral medications, anti-inflammatory medications, and others. Presently, antiviral medication segment dominates the global market in 2020, and is anticipated to continue this trend during the forecast period. The key factors such as rise in demand for treatment of herpes zoster, and active government participation in immunization programs.
By Treatment Type
Antiviral Medications holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Route of Administration Segment Review
On the basis of route of administration, the market is segregated into oral, and topical. At present, the oral segment accounts for the majority of herpes zoster treatment market share, owing to rise in oral medication such as antiviral, anti-inflammatory, and other medication and is treated with oral, topical medications in both developed as well as developing countries, surge in demand of treatment, and surge in geriatric population.
Distribution Channel Segment Review
On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. the drug stores & retail pharmacies segment accounts for the majority of herpes zoster treatment market share, owing to rise in diagnosis of infections, increasing awareness about the use of herpes zoster drugs, and an increase in the adoption of herpes zoster treatment. In addition, increase in government initiatives to promote healthy lifestyle drives the growth of the market.
By Route Of Administration
Oral segment is projected as one of the most lucrative segment.
Region segment review
By region, the herpes zoster treatment market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This was attributed to increase in geriatric population, rise in patient awareness towards treatment of herpes zoster, surge in demand drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the region, and surge in investment made by governments in the healthcare system.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 4.70% during the forecast period.
Key Benefits For Stakeholders
- This report provides a detailed quantitative analysis of the current herpes zoster treatment market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth herpes zoster treatment market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
- A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
- The projections in this report are made by analyzing the current trends and future herpes zoster treatment market potential from 2021 to 2030, in terms of value.
- An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the herpes zoster treatment market.
Herpes Zoster Treatment Market Report Highlights
| Aspects | Details |
 By Treatment Type |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
This section provides opinions of top level analyst in the herpes zoster treatment market. According to analyst, substantial increase in research and development activities, availability of effective drugs, increase in government support for various vaccinations, awareness programs and funds provided by them, and increasing geriatric population drives growth of the herpes zoster treatment market.
As per analyst, increase in patient awareness toward drug therapies, rise in prevalence rate of shingles in older population, and predominance of effective antibodies are the prime reasons that drive growth of the herpes zoster treatment market. Furthermore, dearth of skilled professionals is expected to hinder growth of the market. Moreover, increase in drug development provides lucrative growth opportunities to the market.
They further added that North America is expected to remain dominant during the forecast period, owing to increase in demand for herpes zoster treatment, surge in demand for drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the region, surge in investments made by governments in the healthcare system, and presence of major key players in this region. Moreover, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period, owing to increase in number of hospitals and diagnosis centers with advanced medical facilities along with surge in availability of advanced herpes zoster treatment.
The total market value of herpes zoster treatment market is $217.09 million in 2020.
The forecast period for herpes zoster treatment market is 2021 to 2030
The market value of herpes zoster treatment market in 2021 is $224.90 million.
The base year is 2020 in herpes zoster treatment market
Top companies such as Abbott Laboratory, Bausch Health, Cipla Inc., Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd
Antiviral medication segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to rise in demand for treatment of herpes zoster and active government participation in immunization programs.
Increase in geriatric population, coupled with rising incidences of herpes zoster is anticipated to drive the market in the forecast period.
North America is projected to account for a major share of the global herpes zoster treatment market during the forecast period. U.S. holds the major share due to increase in geriatric population, rise in patient awareness toward treatment of herpes zoster, surge in demand drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the country.
Loading Table Of Content...
